| June 1, 2027 |
BMY |
Single and Multiple Dose Study to Evaluate Safety and Pharmacokinetics of BMS-986533 in Healthy Participants and Assessments of Food and pH Effects on Relative Bioavailability, and Drug-Drug Interaction Potential in Healthy Participants |
Trial Milestone |
Phase 1 |
| June 1, 2027 |
INCY |
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease |
Trial Milestone |
Phase 2 |
| June 1, 2027 |
AAPG |
APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors |
Trial Milestone |
Phase 1/Phase 2 |
| June 1, 2027 |
EIKN |
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors |
Trial Milestone |
Phase 1/Phase 2 |
| June 2, 2027 |
NVS |
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib |
Trial Milestone |
Phase 3 |
| June 7, 2027 |
SNY |
Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age |
Trial Milestone |
Phase 3 |
| June 9, 2027 |
NVS |
Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study |
Trial Milestone |
Phase 4 |
| June 9, 2027 |
NVO |
Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema |
Trial Milestone |
Phase 3 |
| June 15, 2027 |
LLY |
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease |
Trial Milestone |
Phase 2 |
| June 15, 2027 |
ABBV |
Study to Assess Participant Satisfaction After Jawline and Neck Treatment |
Trial Milestone |
Phase 4 |
| June 15, 2027 |
BNTX |
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy |
Trial Milestone |
Phase 2 |
| June 15, 2027 |
BNTX |
A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa |
Trial Milestone |
Phase 2 |
| June 15, 2027 |
IONS |
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen |
Trial Milestone |
Phase 3 |
| June 15, 2027 |
RVMD |
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC |
Trial Milestone |
Phase 1/Phase 2 |
| June 15, 2027 |
ARWR |
Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease |
Trial Milestone |
Phase 1/Phase 2 |
| June 15, 2027 |
ALKS |
A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304) |
Trial Milestone |
Phase 3 |
| June 15, 2027 |
FDMT |
4D-710 in Adult Patients With Cystic Fibrosis |
Trial Milestone |
Phase 2 |
| June 15, 2027 |
FDMT |
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration |
Trial Milestone |
Phase 3 |
| June 15, 2027 |
KPTI |
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia |
Trial Milestone |
Phase 2 |
| June 15, 2027 |
VSTM |
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer |
Trial Milestone |
Phase 2 |
| June 15, 2027 |
VSTM |
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer |
Trial Milestone |
Phase 2 |
| June 15, 2027 |
VSTM |
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer |
Trial Milestone |
Phase 2 |
| June 15, 2027 |
MANE |
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA) |
Trial Milestone |
Phase 3 |
| June 15, 2027 |
BSX |
TheraSphere With Durvalumab and Tremelimumab for HCC |
Trial Milestone |
Phase 2 |
| June 15, 2027 |
VRCA |
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2) |
Trial Milestone |
Phase 3 |
| June 15, 2027 |
DNLI |
An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007 |
Trial Milestone |
Phase 2/Phase 3 |
| June 15, 2027 |
HUMA |
To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis |
Trial Milestone |
Phase 3 |
| June 15, 2027 |
LBRX |
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia |
Trial Milestone |
Phase 3 |
| June 15, 2027 |
SVRA |
Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP). |
Trial Milestone |
Phase 3 |
| June 15, 2027 |
ALXO |
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors |
Trial Milestone |
Phase 1 |
| June 15, 2027 |
GENB |
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer |
Trial Milestone |
Phase 1 |
| June 15, 2027 |
PHVS |
Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency |
Trial Milestone |
Phase 3 |
| June 15, 2027 |
PHVS |
Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema |
Trial Milestone |
Phase 2/Phase 3 |
| June 15, 2027 |
ORKA |
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis |
Trial Milestone |
Phase 2 |
| June 15, 2027 |
SLDB |
A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) |
Trial Milestone |
Phase 1 |
| June 15, 2027 |
TNGX |
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors |
Trial Milestone |
Phase 1/Phase 2 |
| June 15, 2027 |
TNGX |
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients |
Trial Milestone |
Phase 1/Phase 2 |
| June 15, 2027 |
PBH |
To Compare the Pharmacokinetics and Safety of PBP1502 and Humira in Healthy Subjects |
Trial Milestone |
Phase 1 |
| June 15, 2027 |
ORIC |
Study of ORIC-944 in Patients With Metastatic Prostate Cancer |
Trial Milestone |
Phase 1 |
| June 15, 2027 |
CRVS |
Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD |
Trial Milestone |
Phase 2 |
| June 15, 2027 |
VTVT |
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systems |
Trial Milestone |
Phase 2 |
| June 15, 2027 |
AVLN |
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis |
Trial Milestone |
Phase 2 |
| June 15, 2027 |
SYRE |
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis |
Trial Milestone |
Phase 2 |
| June 15, 2027 |
RXRX |
Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP) |
Trial Milestone |
Phase 1/Phase 2 |
| June 15, 2027 |
CRSP |
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias |
Trial Milestone |
Phase 1 |
| June 15, 2027 |
RNXT |
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC |
Trial Milestone |
Phase 3 |
| June 15, 2027 |
NTHI |
A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors |
Trial Milestone |
Phase 1 |
| June 15, 2027 |
KYMR |
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis |
Trial Milestone |
Phase 2 |
| June 15, 2027 |
IRON |
A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD) |
Trial Milestone |
Phase 1 |
| June 15, 2027 |
AKBA |
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS) |
Trial Milestone |
Phase 2 |
| June 16, 2027 |
PFE |
A Study of Sigvotatug Vedotin in Advanced Solid Tumors |
Trial Milestone |
Phase 1 |
| June 16, 2027 |
MRNA |
A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) |
Trial Milestone |
Phase 4 |
| June 21, 2027 |
SNY |
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma |
Trial Milestone |
Phase 2 |
| June 28, 2027 |
JNJ |
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis |
Trial Milestone |
Phase 2 |
| June 30, 2027 |
AZN |
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours |
Trial Milestone |
Phase 1/Phase 2 |
| June 30, 2027 |
JNJ |
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis |
Trial Milestone |
Phase 2/Phase 3 |
| June 30, 2027 |
AMGN |
A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis |
Trial Milestone |
Phase 3 |
| June 30, 2027 |
AMGN |
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) |
Trial Milestone |
Phase 3 |
| June 30, 2027 |
AAPG |
Study of Olverembatinib (HQP1351) in Patients With CML-CP |
Trial Milestone |
Phase 3 |
| June 30, 2027 |
ALNY |
HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB |
Trial Milestone |
Phase 2 |
| June 30, 2027 |
MIRM |
A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2) |
Trial Milestone |
Phase 3 |
| June 30, 2027 |
MGTX |
A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa |
Trial Milestone |
Phase 3 |
| June 30, 2027 |
BLTE |
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy |
Trial Milestone |
Phase 3 |
| June 30, 2027 |
IMNN |
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
Trial Milestone |
Phase 1/Phase 2 |
| June 30, 2027 |
CLRB |
Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG |
Trial Milestone |
Phase 1 |
| June 30, 2027 |
CLRB |
Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas |
Trial Milestone |
Phase 1 |